Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
| Image |  |
|---|---|
| Description | scientific article published on 3 May 2018 |
| Author/s |
author: Michael Wang Felipe Samaniego Nathan H Fowler Luis E. Fayad Michelle A Fanale L Jeffrey Medeiros Anas Younes Sattva S Neelapu Hagop Kantarjian Yasuhiro Oki Andre H Goy Jorge Romaguera Fredrick B Hagemeister Kimberly Hartig Larry Kwak Peter J McLaughlin Robert Z Orlowski |
| Publication date | May 3, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |